SlideShare a Scribd company logo
PROBLEM
Sample size and power calculations can be highly depen-
dent on the assumed magnitude of the treatment effect.
Sensitivity analysis is typically performed by checking calcu-
lations for a range of potential values. Indeed, East is ideally
suited for performing sensitivity analysis of this kind.
This ad hoc approach to sensitivity analysis can be comple-
mented by a Bayesian approach, which addresses uncer-
tainty about the treatment effect in a more formal fashion.
The assurance (O’Hagan et al., 2005), or probability of
success, is a Bayesian version of power, which corresponds
to the unconditional probability that the trial will yield a
significant result. Specifically, it is the expectation of the
power, averaged over a prior distribution for the unknown
treatment effect. This prior distribution expresses the
uncertainty about the treatment effect, before the trial
began, in terms of the relative plausibility of different
parameter values.
Depending on one's goals, a prior distribution can take one
of many forms. It may be non-informative (e.g., uniform); it
may represent the beliefs of an "enthusiastic" or "skeptical"
stakeholder, or it may adopt a complex shape that
represents diverse opinions from a group of experts.
The probability of success is an important consideration for
your clinical trial at the design stage. Another Bayesian
measure, known as predictive power (Lan et al., 2009) aids
decision making at the interim monitoring stage. During the
course of a trial, it is often helpful to calculate the condi-
tional power: the probability of obtaining a significant result
when the trial ends, given the current results. If the condi-
tional power is low, the trial may stop early for futility, or
there may be an opportunity to re-estimate and increase
the sample size.
As with computing power in the design stage, the condition-
al power calculation depends on the assumed treatment
effect, such as an estimate at the interim. However, empiri-
cal estimates may not be reliable. Thus, rather than assum-
ing a single value for the treatment effect, one could calcu-
late conditional power for several different values, and
weigh them by the posterior distribution for the treatment
effect.
PROBLEM - Uncertainty about treatment effects impede clinical trial design
SOLUTION - East® allows Bayesian calculations to formally address this uncertainty
BENEFITS - Ability to incorporate prior information leads to more accurate predictions of trial success
Bayesian Power Calculations:
Probability of Success and Predictive Power
…assurance should be a
major consideration when
designing a confirmatory
trial.
-Chuang-Stein, et al. (2011)
Case Study
East offers the flexibility to use a standard parametric prior
distribution, or a user-defined CSV file for more complex
prior distributions. Bayesian measures, such as assurance and
predictive power, are calculated from these priors.
Suppose we are designing a group sequential clinical trial for a
weight loss treatment, with the inputs displayed above. In
particular, note that we target 90% power to detect a treat-
ment difference of 3 kg.
This calculation rests on the assumption that the magnitude of
the treatment effect (3 kg) is known with certainty. A more
realistic scenario is that the true treatment effect lies within
some range of possible values. The uncertainty about the
treatment effect can be represented, for example, as a
Normal distribution with mean 3, and standard deviation of 2.
In this more realistic scenario, East shows that the probability
of success (72%) is lower than the desired 90% power.
Once the trial is underway, the interim monitoring dashboard
in East can compare the conditional power calculated at the
estimated treatment effect, the predictive power based on a
posterior distribution derived from a diffuse prior, and the
Bayes predictive power based on a posterior distribution
derived from the user-specified prior. The difference in these
three estimate are striking and highlight the importance of
incorporating prior beliefs into the decision making, especial-
ly for futility analysis
BENEFITS
The Bayesian approach to statistical decision making is becoming increasingly accepted as a valuable way to manage uncertainty
in clinical trial design and analysis. One key advantage is the ability to incorporate quantitative prior information to support calcula-
tions and decision making. In fact, any prior information about the treatment effect - whether gained from previous trials or from
expert opinions - can be accounted for in a power calculation. As the industry standard software for clinical trial design, East
continues to incorporate Bayesian and related methodologies to improve clinical success rates.
References
Chuang-Stein, C., Kirby, S., Hirsch, I., & Atkinson, G. (2011). The role of
the minimum clinically important difference and its impact on design-
ing a trial. Pharmaceutical Statistics, 10, 250-256.
Lan, K., Hu, P., & Proschan, M. (2009). A conditional power approach
to the evaluation of predictive power. Statistics in Biopharmaceutical
Research, 1, 131-136.
O’Hagan, A., Stevens, J.W., & Campbell, M.J. (2005). Assurance in
clinical trial design. Pharmaceutical Statistics, 4, 187-201.
Bayesian Power Calculations:
Probability of Success and Predictive Power
SOLUTION
www.cytel.com

More Related Content

PPT
Developing a Quality Audit Report for General Practice Prescribing for Hypert...
PDF
Cluster analysis poster by Gracey and Malley
PDF
Lessons from neuropage chapter
PDF
Bigtown simulation model
PPTX
Importance of evidence
PPTX
Living evidence 3
PPT
Introduction to evidence based practice slp6030
PDF
Wright_Bennett_PSI2015
Developing a Quality Audit Report for General Practice Prescribing for Hypert...
Cluster analysis poster by Gracey and Malley
Lessons from neuropage chapter
Bigtown simulation model
Importance of evidence
Living evidence 3
Introduction to evidence based practice slp6030
Wright_Bennett_PSI2015

What's hot (19)

PPTX
Multisource feedback & its utility
PDF
Schmidt and Bateman on implementation of EQ5D in Community setting
PPTX
Non-inferiority and Equivalence Study design considerations and sample size
PPTX
Hendrix 2015 composite endpoints redacted
PDF
Bateman eq5dforkingsfundmeeting march2015
PPTX
2020 trends in biostatistics what you should know about study design - slid...
PDF
Nicholas Jewell MedicReS World Congress 2014
PDF
Clinical data analytics
PPTX
Webinar slides- alternatives to the p-value and power
PPTX
Sample size for survival analysis - a guide to planning successful clinical t...
PPTX
Innovative Sample Size Methods For Clinical Trials
PPTX
Innovative Strategies For Successful Trial Design - Webinar Slides
PPTX
Bases talk for slideshare (atkinson)
PPT
Quantitative Synthesis I
PPTX
Concept map care plan
PPT
SOC2002 Lecture 4
PPTX
Designing studies with recurrent events | Model choices, pitfalls and group s...
PPTX
How to calculate Sample Size
Multisource feedback & its utility
Schmidt and Bateman on implementation of EQ5D in Community setting
Non-inferiority and Equivalence Study design considerations and sample size
Hendrix 2015 composite endpoints redacted
Bateman eq5dforkingsfundmeeting march2015
2020 trends in biostatistics what you should know about study design - slid...
Nicholas Jewell MedicReS World Congress 2014
Clinical data analytics
Webinar slides- alternatives to the p-value and power
Sample size for survival analysis - a guide to planning successful clinical t...
Innovative Sample Size Methods For Clinical Trials
Innovative Strategies For Successful Trial Design - Webinar Slides
Bases talk for slideshare (atkinson)
Quantitative Synthesis I
Concept map care plan
SOC2002 Lecture 4
Designing studies with recurrent events | Model choices, pitfalls and group s...
How to calculate Sample Size
Ad

Similar to East bayesian power calculations (20)

PPTX
Bayesian Assurance: Formalizing Sensitivity Analysis For Sample Size
PDF
Bayesian random effects meta-analysis model for normal data - Pubrica
PPTX
5 essential steps for sample size determination in clinical trials slideshare
PPTX
Bayesian Approaches To Improve Sample Size Webinar
PPTX
Webinar slides sample size for survival analysis - a guide to planning succ...
PPT
Intro To Adaptive Design
PPTX
Practical Methods To Overcome Sample Size Challenges
PDF
Infosheet east-sample-size-re-estimation
PDF
East sample size re estimation
PDF
East Sample Size Re-Estimation Infosheet
PDF
A Lenda do Valor P
PPTX
Sample Size Estimation and Statistical Test Selection
PPTX
APPRAISING EVIDENCE ABOUT CLINICAL PREDICTION RULES.pptx
PDF
Cluster-Specific Propensity Score Weighting To Stabilize Treatment Effect Est...
PDF
Cluster-Specific Propensity Score Weighting To Stabilize Treatment Effect Est...
PDF
An overview of fixed effects assumptions for meta analysis - Pubrica
PPTX
Sample-size-comprehensive.pptx
PDF
Sample Size: A couple more hints to handle it right using SAS and R
PDF
How Randomized Controlled Trials are Used in Meta-Analysis
PPT
Meta analysis
Bayesian Assurance: Formalizing Sensitivity Analysis For Sample Size
Bayesian random effects meta-analysis model for normal data - Pubrica
5 essential steps for sample size determination in clinical trials slideshare
Bayesian Approaches To Improve Sample Size Webinar
Webinar slides sample size for survival analysis - a guide to planning succ...
Intro To Adaptive Design
Practical Methods To Overcome Sample Size Challenges
Infosheet east-sample-size-re-estimation
East sample size re estimation
East Sample Size Re-Estimation Infosheet
A Lenda do Valor P
Sample Size Estimation and Statistical Test Selection
APPRAISING EVIDENCE ABOUT CLINICAL PREDICTION RULES.pptx
Cluster-Specific Propensity Score Weighting To Stabilize Treatment Effect Est...
Cluster-Specific Propensity Score Weighting To Stabilize Treatment Effect Est...
An overview of fixed effects assumptions for meta analysis - Pubrica
Sample-size-comprehensive.pptx
Sample Size: A couple more hints to handle it right using SAS and R
How Randomized Controlled Trials are Used in Meta-Analysis
Meta analysis
Ad

More from Cytel (20)

PDF
StatXact 10 Infosheet
PDF
StatXact 10 Procedures Roadmap
PDF
Stat xact10 infosheet
PDF
Si z slides-multiple comparisons procedures (east) 41pg
PDF
Si z mc-datasheet-
PDF
Si z mc-datasheet- 2
PDF
Si z siz vs. nquery
PDF
Si z multi arm trials
PDF
East ugm-2012-presentation-east-future-mehta
PDF
East Infosheet
PDF
East Bayesian Assurance Infosheet
PDF
East 6.2 Architect Infosheet
PDF
East 6.2 architect-brochure
PDF
East architect brochure
PDF
Compass Infosheet
PDF
Clinical outsourcing
PDF
ACES - What is ACES And Who is Using It
PDF
Aces overview & features
PPTX
Therapeutic Area Standards: Reflections on Oncology Standards and What is Nee...
PPTX
A Systematic Review of ADaM IG Interpretation presented by Angelo Tinazzi, Cytel
StatXact 10 Infosheet
StatXact 10 Procedures Roadmap
Stat xact10 infosheet
Si z slides-multiple comparisons procedures (east) 41pg
Si z mc-datasheet-
Si z mc-datasheet- 2
Si z siz vs. nquery
Si z multi arm trials
East ugm-2012-presentation-east-future-mehta
East Infosheet
East Bayesian Assurance Infosheet
East 6.2 Architect Infosheet
East 6.2 architect-brochure
East architect brochure
Compass Infosheet
Clinical outsourcing
ACES - What is ACES And Who is Using It
Aces overview & features
Therapeutic Area Standards: Reflections on Oncology Standards and What is Nee...
A Systematic Review of ADaM IG Interpretation presented by Angelo Tinazzi, Cytel

East bayesian power calculations

  • 1. PROBLEM Sample size and power calculations can be highly depen- dent on the assumed magnitude of the treatment effect. Sensitivity analysis is typically performed by checking calcu- lations for a range of potential values. Indeed, East is ideally suited for performing sensitivity analysis of this kind. This ad hoc approach to sensitivity analysis can be comple- mented by a Bayesian approach, which addresses uncer- tainty about the treatment effect in a more formal fashion. The assurance (O’Hagan et al., 2005), or probability of success, is a Bayesian version of power, which corresponds to the unconditional probability that the trial will yield a significant result. Specifically, it is the expectation of the power, averaged over a prior distribution for the unknown treatment effect. This prior distribution expresses the uncertainty about the treatment effect, before the trial began, in terms of the relative plausibility of different parameter values. Depending on one's goals, a prior distribution can take one of many forms. It may be non-informative (e.g., uniform); it may represent the beliefs of an "enthusiastic" or "skeptical" stakeholder, or it may adopt a complex shape that represents diverse opinions from a group of experts. The probability of success is an important consideration for your clinical trial at the design stage. Another Bayesian measure, known as predictive power (Lan et al., 2009) aids decision making at the interim monitoring stage. During the course of a trial, it is often helpful to calculate the condi- tional power: the probability of obtaining a significant result when the trial ends, given the current results. If the condi- tional power is low, the trial may stop early for futility, or there may be an opportunity to re-estimate and increase the sample size. As with computing power in the design stage, the condition- al power calculation depends on the assumed treatment effect, such as an estimate at the interim. However, empiri- cal estimates may not be reliable. Thus, rather than assum- ing a single value for the treatment effect, one could calcu- late conditional power for several different values, and weigh them by the posterior distribution for the treatment effect. PROBLEM - Uncertainty about treatment effects impede clinical trial design SOLUTION - East® allows Bayesian calculations to formally address this uncertainty BENEFITS - Ability to incorporate prior information leads to more accurate predictions of trial success Bayesian Power Calculations: Probability of Success and Predictive Power …assurance should be a major consideration when designing a confirmatory trial. -Chuang-Stein, et al. (2011) Case Study
  • 2. East offers the flexibility to use a standard parametric prior distribution, or a user-defined CSV file for more complex prior distributions. Bayesian measures, such as assurance and predictive power, are calculated from these priors. Suppose we are designing a group sequential clinical trial for a weight loss treatment, with the inputs displayed above. In particular, note that we target 90% power to detect a treat- ment difference of 3 kg. This calculation rests on the assumption that the magnitude of the treatment effect (3 kg) is known with certainty. A more realistic scenario is that the true treatment effect lies within some range of possible values. The uncertainty about the treatment effect can be represented, for example, as a Normal distribution with mean 3, and standard deviation of 2. In this more realistic scenario, East shows that the probability of success (72%) is lower than the desired 90% power. Once the trial is underway, the interim monitoring dashboard in East can compare the conditional power calculated at the estimated treatment effect, the predictive power based on a posterior distribution derived from a diffuse prior, and the Bayes predictive power based on a posterior distribution derived from the user-specified prior. The difference in these three estimate are striking and highlight the importance of incorporating prior beliefs into the decision making, especial- ly for futility analysis BENEFITS The Bayesian approach to statistical decision making is becoming increasingly accepted as a valuable way to manage uncertainty in clinical trial design and analysis. One key advantage is the ability to incorporate quantitative prior information to support calcula- tions and decision making. In fact, any prior information about the treatment effect - whether gained from previous trials or from expert opinions - can be accounted for in a power calculation. As the industry standard software for clinical trial design, East continues to incorporate Bayesian and related methodologies to improve clinical success rates. References Chuang-Stein, C., Kirby, S., Hirsch, I., & Atkinson, G. (2011). The role of the minimum clinically important difference and its impact on design- ing a trial. Pharmaceutical Statistics, 10, 250-256. Lan, K., Hu, P., & Proschan, M. (2009). A conditional power approach to the evaluation of predictive power. Statistics in Biopharmaceutical Research, 1, 131-136. O’Hagan, A., Stevens, J.W., & Campbell, M.J. (2005). Assurance in clinical trial design. Pharmaceutical Statistics, 4, 187-201. Bayesian Power Calculations: Probability of Success and Predictive Power SOLUTION www.cytel.com